Inflammasome proteins in cerebrospinal fluid of brain-injured patients as biomarkers of functional outcome

Clinical article

Stephanie Adamczak, Gordon Dale, Juan Pablo P de Rivero Vaccari, Ross Bullock, W. Dalton Dietrich, Robert Keane

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Object. Traumatic brain injury (TBI), the third most common CNS pathology, plagues 5.3 million Americans with permanent TBI-related disabilities. To evaluate injury severity and prognosis, physicians rely on clinical variables. Here, the authors seek objective, biochemical markers reflecting molecular injury mechanisms specific to the CNS as more accurate measurements of injury severity and outcome. One such secondary injury mechanism, the innate immune response, is regulated by the inflammasome, a molecular platform that activates caspase-1 and interleukin-1β. Methods. The authors investigated whether inflammasome components were present in the CSF of 23 patients with TBI and whether levels of inflammasome components correlate with outcome. The authors performed an immunoblot analysis of CSF samples from patients who suffered TBI and nontrauma controls and assessed the outcomes 5 months postinjury by using the Glasgow Outcome Scale. Data were analyzed using Mann-Whitney U-tests and linear regression analysis. Results. Patients with severe or moderate cranial trauma exhibited significantly higher CSF levels of the inflammasome proteins ASC, caspase-1, and NALP-1 than nontrauma controls (p < 0.0001, p = 0.0029, and p = 0.0202, respectively). Expression of each protein correlated significantly with the Glasgow Outcome Scale score at 5 months postinjury (p < 0.05). ASC, caspase-1, and NALP-1 were significantly higher in the CSF of patients with unfavorable outcomes, including death and severe disability (p < 0.0001). Conclusions. NALP-1 inflammasome proteins are potential biomarkers to assess TBI severity, outcome, and the secondary injury mechanisms impeding recovery, serving as adjuncts to clinical predictors.

Original languageEnglish
Pages (from-to)1119-1125
Number of pages7
JournalJournal of Neurosurgery
Volume117
Issue number6
DOIs
StatePublished - Dec 1 2012

Fingerprint

Inflammasomes
Cerebrospinal Fluid Proteins
Biomarkers
Caspase 1
Wounds and Injuries
Brain
Glasgow Outcome Scale
Proteins
Plague
Nonparametric Statistics
Interleukin-1
Innate Immunity
Linear Models
Regression Analysis
Traumatic Brain Injury
Pathology
Physicians

Keywords

  • Biomarker
  • Inflammasome
  • Inflammation
  • Innate immunity
  • Traumatic brain injury

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

Inflammasome proteins in cerebrospinal fluid of brain-injured patients as biomarkers of functional outcome : Clinical article. / Adamczak, Stephanie; Dale, Gordon; de Rivero Vaccari, Juan Pablo P; Bullock, Ross; Dalton Dietrich, W.; Keane, Robert.

In: Journal of Neurosurgery, Vol. 117, No. 6, 01.12.2012, p. 1119-1125.

Research output: Contribution to journalArticle

@article{4f38cf2ff314405a874bb6cd576e6cdc,
title = "Inflammasome proteins in cerebrospinal fluid of brain-injured patients as biomarkers of functional outcome: Clinical article",
abstract = "Object. Traumatic brain injury (TBI), the third most common CNS pathology, plagues 5.3 million Americans with permanent TBI-related disabilities. To evaluate injury severity and prognosis, physicians rely on clinical variables. Here, the authors seek objective, biochemical markers reflecting molecular injury mechanisms specific to the CNS as more accurate measurements of injury severity and outcome. One such secondary injury mechanism, the innate immune response, is regulated by the inflammasome, a molecular platform that activates caspase-1 and interleukin-1β. Methods. The authors investigated whether inflammasome components were present in the CSF of 23 patients with TBI and whether levels of inflammasome components correlate with outcome. The authors performed an immunoblot analysis of CSF samples from patients who suffered TBI and nontrauma controls and assessed the outcomes 5 months postinjury by using the Glasgow Outcome Scale. Data were analyzed using Mann-Whitney U-tests and linear regression analysis. Results. Patients with severe or moderate cranial trauma exhibited significantly higher CSF levels of the inflammasome proteins ASC, caspase-1, and NALP-1 than nontrauma controls (p < 0.0001, p = 0.0029, and p = 0.0202, respectively). Expression of each protein correlated significantly with the Glasgow Outcome Scale score at 5 months postinjury (p < 0.05). ASC, caspase-1, and NALP-1 were significantly higher in the CSF of patients with unfavorable outcomes, including death and severe disability (p < 0.0001). Conclusions. NALP-1 inflammasome proteins are potential biomarkers to assess TBI severity, outcome, and the secondary injury mechanisms impeding recovery, serving as adjuncts to clinical predictors.",
keywords = "Biomarker, Inflammasome, Inflammation, Innate immunity, Traumatic brain injury",
author = "Stephanie Adamczak and Gordon Dale and {de Rivero Vaccari}, {Juan Pablo P} and Ross Bullock and {Dalton Dietrich}, W. and Robert Keane",
year = "2012",
month = "12",
day = "1",
doi = "10.3171/2012.9.JNS12815",
language = "English",
volume = "117",
pages = "1119--1125",
journal = "Journal of Neurosurgery",
issn = "0022-3085",
publisher = "American Association of Neurological Surgeons",
number = "6",

}

TY - JOUR

T1 - Inflammasome proteins in cerebrospinal fluid of brain-injured patients as biomarkers of functional outcome

T2 - Clinical article

AU - Adamczak, Stephanie

AU - Dale, Gordon

AU - de Rivero Vaccari, Juan Pablo P

AU - Bullock, Ross

AU - Dalton Dietrich, W.

AU - Keane, Robert

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Object. Traumatic brain injury (TBI), the third most common CNS pathology, plagues 5.3 million Americans with permanent TBI-related disabilities. To evaluate injury severity and prognosis, physicians rely on clinical variables. Here, the authors seek objective, biochemical markers reflecting molecular injury mechanisms specific to the CNS as more accurate measurements of injury severity and outcome. One such secondary injury mechanism, the innate immune response, is regulated by the inflammasome, a molecular platform that activates caspase-1 and interleukin-1β. Methods. The authors investigated whether inflammasome components were present in the CSF of 23 patients with TBI and whether levels of inflammasome components correlate with outcome. The authors performed an immunoblot analysis of CSF samples from patients who suffered TBI and nontrauma controls and assessed the outcomes 5 months postinjury by using the Glasgow Outcome Scale. Data were analyzed using Mann-Whitney U-tests and linear regression analysis. Results. Patients with severe or moderate cranial trauma exhibited significantly higher CSF levels of the inflammasome proteins ASC, caspase-1, and NALP-1 than nontrauma controls (p < 0.0001, p = 0.0029, and p = 0.0202, respectively). Expression of each protein correlated significantly with the Glasgow Outcome Scale score at 5 months postinjury (p < 0.05). ASC, caspase-1, and NALP-1 were significantly higher in the CSF of patients with unfavorable outcomes, including death and severe disability (p < 0.0001). Conclusions. NALP-1 inflammasome proteins are potential biomarkers to assess TBI severity, outcome, and the secondary injury mechanisms impeding recovery, serving as adjuncts to clinical predictors.

AB - Object. Traumatic brain injury (TBI), the third most common CNS pathology, plagues 5.3 million Americans with permanent TBI-related disabilities. To evaluate injury severity and prognosis, physicians rely on clinical variables. Here, the authors seek objective, biochemical markers reflecting molecular injury mechanisms specific to the CNS as more accurate measurements of injury severity and outcome. One such secondary injury mechanism, the innate immune response, is regulated by the inflammasome, a molecular platform that activates caspase-1 and interleukin-1β. Methods. The authors investigated whether inflammasome components were present in the CSF of 23 patients with TBI and whether levels of inflammasome components correlate with outcome. The authors performed an immunoblot analysis of CSF samples from patients who suffered TBI and nontrauma controls and assessed the outcomes 5 months postinjury by using the Glasgow Outcome Scale. Data were analyzed using Mann-Whitney U-tests and linear regression analysis. Results. Patients with severe or moderate cranial trauma exhibited significantly higher CSF levels of the inflammasome proteins ASC, caspase-1, and NALP-1 than nontrauma controls (p < 0.0001, p = 0.0029, and p = 0.0202, respectively). Expression of each protein correlated significantly with the Glasgow Outcome Scale score at 5 months postinjury (p < 0.05). ASC, caspase-1, and NALP-1 were significantly higher in the CSF of patients with unfavorable outcomes, including death and severe disability (p < 0.0001). Conclusions. NALP-1 inflammasome proteins are potential biomarkers to assess TBI severity, outcome, and the secondary injury mechanisms impeding recovery, serving as adjuncts to clinical predictors.

KW - Biomarker

KW - Inflammasome

KW - Inflammation

KW - Innate immunity

KW - Traumatic brain injury

UR - http://www.scopus.com/inward/record.url?scp=84870925761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870925761&partnerID=8YFLogxK

U2 - 10.3171/2012.9.JNS12815

DO - 10.3171/2012.9.JNS12815

M3 - Article

VL - 117

SP - 1119

EP - 1125

JO - Journal of Neurosurgery

JF - Journal of Neurosurgery

SN - 0022-3085

IS - 6

ER -